A study of two new encorafenib formulations and the effect of a proton-pump inhibitor on these formulations in adult healthy participants. A Phase 1, Randomized, Open-Label Study in Healthy Participants to Estimate the Bioavailability of Two New Encorafenib Formulations Relative to the Current Formulation and to Evaluate the Effect of a Proton-Pump Inhibitor on Encorafenib Plasma Pharmacokinetics.